Genzyme troubles boost Icahn proxy bid

Right now, anything that costs Genzyme a significant amount of money and damages its reputation is a big plus for Carl Icahn. And Icahn had good reason to celebrate the big black eye Genzyme got from yesterday's news that the FDA will return to its Allston Landing facility in Boston and take a bigger role in overseeing its operations, a move that will likely pave the way to a considerable government fine. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.